SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CERS

Cerus Corp (NASDAQ:CERS)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$1.85-$0.05 (-2.63%)
 
Market cap
$374M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 31, 1997
Website
Market Cap$373.61M+14.2%
Revenue (ttm)$226.57M+13.7%
Net Income-$7.31M+54.2%
EPS-$0.04+54.2%
Shares Out201.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,512,960
Open$1.84
Previous Close$1.90
Day's Range$1.82 - $1.95
52-Week Range$1.59 - $3.47
Beta1.85
AnalystsBuy
Price Target$4.00(+116.22%)
Earnings DateMar 1, 2027

About CERS

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

Address
1220 Concord Avenue, Concord, CA, 94520, US
Market Cap
374 million
Employees
268
Industrial Classification
Medical - Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.58M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Sound
From CERS’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.63%
5 Days
-5.61%
1 Month
-22.59%
6 Months
-32.48%
1 Year
+14.20%

$CERS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CERS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CERS's directors and management

Net Shares Purchased by Insiders−1M−500k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CERS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CERS Revenue by Segment or Geography

CERS's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CERS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CERS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CERS

ARKKARK Innovation ETF$31.00M
ARKGARK Genomic Revolution ETF$15.79M
VTIVanguard Morningstar Total Stock Market ETF$10.92M
IWMiShares Russell 2000 ETF$9.93M
VXFVanguard Extended Market ETF$5.12M
IWOiShares Russell 2000 Growth ETF$3.63M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CERS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ARKGARK Genomic Revolution ETF0.85%
XHEState Street SPDR S&P Health Care Equipment ETF0.74%
QQQSInvesco NASDAQ Future Gen 200 ETF0.45%
FSMLFranklin Small Cap Enhanced ETF0.40%
ARKKARK Innovation ETF0.30%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.13%
FVIFirst Trust Total US Market AlphaDEX ETF0.11%
IWCiShares Micro-Cap ETF0.10%
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF0.06%
VFMOVanguard U.S. Momentum Factor ETF0.06%
SMLFiShares U.S. Small-Cap Equity Factor ETF0.05%
FESMFidelity Enhanced Small Cap ETF0.05%

Weight is the stock’s share of each fund’s holdings.